GSE49423
Acute Genome-Wide Effects of Rosiglitazone on PPAR? Transcriptional Networks in Adipocytes
Here we report, for the first time, the acute effects of the synthetic PPAR? agonist rosiglitazone on the transcriptional network of PPAR? in adipocytes. Treatment with Rosiglitazone for 1 hour leads to acute transcriptional activation as well as repression of a number of genes as determined by genome-wide RNA polymerase II occupancy. Unlike what has been shown for many other nuclear receptors, agonist treatment does not lead to major changes in the occurrence of PPAR? binding sites. However, rosiglitazone promotes PPAR? occupancy at many preexisting sites, and this is paralleled by increased occupancy of the mediator subunit MED1. The increase in PPAR? and MED1 binding is correlated with an increase in transcription of nearby genes indicating that rosiglitazone, in addition to activating the receptor, also promotes its association with DNA, and that this is causally linked to recruitment of mediator and activation of genes. Notably, both Rosiglitazone-activated and -repressed genes are induced during adipogenesis. However, Rosiglitazone-activated genes are markedly more associated with PPAR? than repressed genes and are highly dependent on PPAR? for expression in adipocytes. By contrast, repressed genes are associated with the other key adipocyte transcription factor CCAAT-Enhancer binding protein (C/EBPa), and their expression is more dependent on C/EBPa. This suggests that the relative occupancies of PPAR? and C/EBPa are critical for whether genes will be induced or repressed by PPAR? agonist. Overall design: Examination of binding of PPAR?, C/EBPa, RNAPII, CBP and MED1 in mature 3T3-L1 adipocytes treated with 1 µM Rosiglitazone and/or 0.1% DMSO for 1 hour.